PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 1989 February; 52(2): 201–206.
PMCID: PMC1032506

Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Abstract

In order to investigate the neuronal basis of cognitive disorders in Parkinson's disease, the neuropsychological performance of 120 patients with idiopathic Parkinson's disease was analysed in relation to motor symptoms as a function of their response to levodopa. Cognitive impairment was poorly correlated with akinesia and rigidity, symptoms which respond well to levodopa treatment, and was not correlated at all with that part of the patients' motor score that could be improved by the drug. In contrast, strong correlations were found between all neuropsychological test scores and axial symptoms such as gait disorder and dysarthria, which respond little if at all to levodopa treatment. The neuropsychological test scores were also strongly correlated with the motor score of patients estimated when clinical improvement was maximal under levodopa treatment. This score is assumed to represent residual non-dopaminergic motor dysfunctions. The correlations suggest that much of the cognitive impairment in Parkinson's disease results from the dysfunction of non-dopaminergic neuronal systems.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (957K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Loranger AW, Goodell H, Lee JE, McDowell F. Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning. Arch Gen Psychiatry. 1972 Feb;26(2):163–168. [PubMed]
  • Riklan M, Whelihan W, Cullinan T. Levodopa and psychometric test performance in parkinsonism-5 years later. Neurology. 1976 Feb;26(2):173–179. [PubMed]
  • Rogers D, Lees AJ, Smith E, Trimble M, Stern GM. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain. 1987 Jun;110(Pt 3):761–776. [PubMed]
  • Delis D, Direnfeld L, Alexander MP, Kaplan E. Cognitive fluctuations associated with on-off phenomenon in Parkinson disease. Neurology. 1982 Sep;32(9):1049–1052. [PubMed]
  • Mortimer JA, Pirozzolo FJ, Hansch EC, Webster DD. Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology. 1982 Feb;32(2):133–137. [PubMed]
  • Stern Y, Langston JW. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 1985 Oct;35(10):1506–1509. [PubMed]
  • Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546–4550. [PubMed]
  • Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979 Dec;1(3):249–254. [PubMed]
  • Halgin R, Riklan M, Misiak H. Levodopa, parkinsonism, and recent memory. J Nerv Ment Dis. 1977 Apr;164(4):268–272. [PubMed]
  • Marsh GG, Markham CM, Ansel R. Levodopa's awakening effect on patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971 Jun;34(3):209–218. [PMC free article] [PubMed]
  • Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984 May;47(5):454–465. [PMC free article] [PubMed]
  • Girotti F, Carella F, Grassi MP, Soliveri P, Marano R, Caraceni T. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry. 1986 Jun;49(6):657–660. [PMC free article] [PubMed]
  • Rafal RD, Posner MI, Walker JA, Friedrich FJ. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease. Brain. 1984 Dec;107(Pt 4):1083–1094. [PubMed]
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. [PubMed]
  • Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y. Le test à la L-Dopa dans la maladie de Parkinson. Rev Neurol (Paris) 1985;141(5):413–415. [PubMed]
  • Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol. 1978 May;35(5):261–263. [PubMed]
  • Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology. 1987 Sep;37(9):1539–1542. [PubMed]
  • Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex. 1976 Dec;12(4):313–324. [PubMed]
  • Lhermitte F, Pillon B, Serdaru M. Human autonomy and the frontal lobes. Part I: Imitation and utilization behavior: a neuropsychological study of 75 patients. Ann Neurol. 1986 Apr;19(4):326–334. [PubMed]
  • Pirozzolo FJ, Hansch EC, Mortimer JA, Webster DD, Kuskowski MA. Dementia in Parkinson disease: a neuropsychological analysis. Brain Cogn. 1982 Jan;1(1):71–83. [PubMed]
  • Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol. 1988 Nov;45(11):1194–1199. [PubMed]
  • Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 1983 Jun;106(Pt 2):257–270. [PubMed]
  • Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain. 1986 Oct;109(Pt 5):845–883. [PubMed]
  • Portin R, Rinne UK. Predictive factors for cognitive deterioration and dementia in Parkinson's disease. Adv Neurol. 1987;45:413–416. [PubMed]
  • Lieberman A, Dziatolowski M, Kupersmith M, Serby M, Goodgold A, Korein J, Goldstein M. Dementia in Parkinson Disease. Ann Neurol. 1979 Oct;6(4):355–359. [PubMed]
  • Elizan TS, Sroka H, Maker H, Smith H, Yahr MD. Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients. J Neural Transm. 1986;65(3-4):285–302. [PubMed]
  • Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology. 1985 Apr;35(4):522–526. [PubMed]
  • Loranger AW, Goodell H, McDowell FH, Lee JE, Sweet RD. Intellectual impairment in Parkinson's syndrome. Brain. 1972;95(2):405–412. [PubMed]
  • Garron DC, Klawans HL, Jr, Narin F. Intellectual functioning of persons with idiopathic Parkinsonism. J Nerv Ment Dis. 1972 Jun;154(6):445–452. [PubMed]
  • Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst. 1972 Sep;33(9):577–583. [PubMed]
  • Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. [PubMed]
  • Marttila RJ, Rinne UK. Dementia in Parkinson's disease. Acta Neurol Scand. 1976 Nov;54(5):431–441. [PubMed]
  • Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in Parkinson's disease. Arch Neurol. 1982 Oct;39(10):666–667. [PubMed]
  • Perry RH, Tomlinson BE, Candy JM, Blessed G, Foster JF, Bloxham CA, Perry ER. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet. 1983 Oct 1;2(8353):789–790. [PubMed]
  • Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res. 1983 Dec 12;288(1-2):213–218. [PubMed]
  • Dubois B, Danzé F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol. 1987 Jul;22(1):26–30. [PubMed]
  • Cash R, Dennis T, L'Heureux R, Raisman R, Javoy-Agid F, Scatton B. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology. 1987 Jan;37(1):42–46. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group